Matinas BioPharma Holdings, Inc. (MTNB) — 分析师展望 / 分析师共识目标价为. 基于 8 位分析师评级, 共识为 看涨 — 7 买入, 1 持有.
分析师预估 每股收益(EPS)为 $-4.06 和 营收为 $0.00B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-4.98 vs 预期 $-4.06 (不及预期 -22.7%). 2025: 实际 $-2.00 vs 预期 $-1.50 (不及预期 -33.3%). 分析师准确度: 78%.
MTNB 分析师评级
Buy
基于过去3个月内 8 位分析师对 Matinas BioPharma Holdings, Inc. 的评级
EPS 预测 — MTNB
78%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$4.98
vs Est –$4.06
▼ 18.5% off
2025
Actual –$2.00
vs Est –$1.50
▼ 25.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — MTNB
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
